Photo: open.spotify.com
Apr 21, 2026, 14:44
Continuing the Conversation on Factor VIII – EAHAD
European Association for Haemophilia and Allied Disorders (EAHAD), shared a post on LinkedIn:
”Continuing the conversation on Factor VIII!
As innovations such as emicizumab, rebalancing agents, and gene therapy continue to transform care, what is the place of FVIII today, and where is it heading next?”
Stay updated with Hemostasis Today.
-
Jun 16, 2026, 09:26William Aird: Introducing The Blood Project’s CAD Topic Module
-
Jun 16, 2026, 08:23Jessica O’Logbon: Maternal Hemoglobin and Early Neonatal Outcomes
-
Jun 16, 2026, 03:15Linda S. Barnes: Blood Deserts Are a Global Health Challenge
-
Jun 15, 2026, 18:24Celebrating Emna Gouider’s Renewed Leadership at WFH Congress 2026 – WFH
-
Jun 15, 2026, 18:14Anastasia Conti: Connecting Celebrating and Advancing Hematology at EHA 2026
-
Jun 15, 2026, 18:01Eric Mwenda: Honoring Blood Donors and Partnerships in Tanzania
-
Jun 15, 2026, 17:37Vincent Elsey: The Ethereal Anatomy of a Broken Vessel
-
Jun 15, 2026, 17:20Megan Adediran: Small Act, Massive Impact – Celebrating Blood Donor Day
-
Jun 15, 2026, 16:52Alejandro González Veliz: A Modern Approach to Anticoagulant Management